Step 1: Recall the principle. Antiretroviral therapy in pregnancy uses a two-NRTI backbone combined with a third agent (an integrase inhibitor, NNRTI or boosted protease inhibitor).
Step 2: List the accepted backbones. The preferred dual-NRTI backbones all cross the placenta well and include tenofovir disoproxil fumarate plus emtricitabine, tenofovir disoproxil fumarate plus lamivudine, and abacavir plus lamivudine (the last only if HLA-B5701 negative).
Step 3: Choose the answer. Since all three listed pairs are acceptable backbone regimens, the correct response is all. Options A, B and C are each individually valid, so no single one can be the sole answer.